Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy

Table 2 Adverse events during MASCT treatment

Adverse events	DC injection					T cell injection
	Treatment times (n = 71)				Patients	Treatment times (n = 100)				Patients
	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)	Grade 4 (%)	n = 13 (%)	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)	Grade 4 (%)	n = 13 (%)
Constitutional symptoms
Fever	2 (2.8)	0 (0)	0 (0)	0 (0)	2 (15.4)	1 (1)	0 (0)	0 (0)	0 (0)	1 (7.7)
Musculoskeletal disorders
Osteodynia	1 (1.4)	0 (0)	0 (0)	0 (0)	1 (7.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Respiratory tract disorders
Cough	1 (1.4)	0 (0)	0 (0)	0 (0)	1 (7.7)	3 (3)	0 (0)	0 (0)	0 (0)	2 (15.4)
Throat	1 (1.4)	0 (0)	0 (0)	0 (0)	1 (7.7)	3 (3)	0 (0)	0 (0)	0 (0)	2 (15.4)
Blood examinations
White blood cell decrease	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (7.7)
Platelet decrease	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	2 (15.4)
Neutrophil decrease	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (7.7)
Hemoglobin decrease	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (7.7)
Immune diseases
Allergic reaction	2 (2.8)	0 (0)	0 (0)	0 (0)	2 (15.4)	3 (3)	0 (0)	0 (0)	0 (0)	2 (15.4)

The grades of adverse events are defined according to common terminology criteria for adverse events (CTCAE)

ISSN: 1479-5876